Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.46 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.46 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.46 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.46 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.46 |
| ▸ | HTR2B | P41595 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13211723 | 0.85 | LMNA (0.41) | LMNATRPA1CHRM1SLC6A2ADRA1A | |
| SCHEMBL16812865 | 0.83 | LMNA (0.47) | LMNATRPA1CHRM1SLC6A2ADRA1A | |
| SCHEMBL12889908 | 0.81 | KCNK3 (0.40) | LMNATRPA1ALDH1A1 | |
| SCHEMBL12868968 | 0.81 | KCNK3 (0.43) | SLC6A2 | |
| SCHEMBL24910322 | 0.81 | PDE2A (0.48) | SLC6A2ALDH1A1 | |
| SCHEMBL12868653 | 0.80 | HRH4 (0.43) | — | |
| SCHEMBL12868655 | 0.80 | CNR2 (0.39) | LMNA | |
| SCHEMBL16961960 | 0.80 | KCNK3 (0.39) | — | |
| SCHEMBL29640497 | 0.78 | LMNA (0.54) | LMNATRPA1CHRM1SLC6A2ADRA1A | |
| SCHEMBL11043528 | 0.78 | LMNA (0.54) | LMNATRPA1CHRM1SLC6A2ADRA1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230265055-A1 | STAT INIHIBITORY COMPOUNDS AND COMPOSITIONS | OXFORD FINANCE LLC | 2023-08-24 | — | — | US | disclosed |
| US-20230159526-A1 | COMPOUNDS FOR INHIBITING NLRP3 AND USES THEREOF | VENTUS THERAPEUTICS U.S., INC. | 2023-05-25 | — | — | US | disclosed |
| US-20230159445-A1 | STAT INHIBITORY COMPOUNDS AND COMPOSITIONS | OXFORD FINANCE LLC | 2023-05-25 | — | — | US | disclosed |
| US-20230137956-A1 | ALPHA SUBSTITUTED STAT INHIBITORS AND COMPOSITIONS THEREOF | OXFORD FINANCE LLC | 2023-05-04 | — | — | US | disclosed |
| US-20200270230-A1 | µ-OPIOID RECEPTOR AGONIST AND PREPARATION METHOD THEREFOR AND USE THEREOF IN FIELD OF MEDICINE | ZHEJIANG HUAHAI PHARMACEUTICAL CO., LTD. (CN) | 2020-08-27 | — | — | US | disclosed |
| EP-2900645-A1 | 3-PHENYLISOXAZOLIN DERIVATIVES WITH HERBICIDAL ACTION | Bayer CropScience AG (DE) | 2015-08-05 | — | — | EP | disclosed |
| US-20120129846-A1 | GAMMA SECRETASE MODULATORS | Merck, Sharp & Dohme, Corp. | 2012-05-24 | — | — | US | disclosed |
| US-7884234-B2 | N-[4-(tert-butyl)benzyl]-N-[4 -(trifluoromethoxy)biphenyl-3-yl]oxamic Acid; Inhibitors of plasminogen activator inhibitor-1 (PAI-1); thrombogenesis, fibrogenesis, accumulation of visceral fat, cell proliferation, angiogenesis | INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) | 2011-02-08 | — | — | US | disclosed |
| US-20110015190-A1 | GAMMA SECRETASE MODULATORS | SCHERING CORPORATION | 2011-01-20 | — | — | US | disclosed |
| US-20090215899-A9 | N-Phenyloxamide derivatives | INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) | 2009-08-27 | — | — | US | disclosed |
| US-20080249175-A1 | N-Phenyloxamide derivatives | INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) | 2008-10-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080249175-A1 | N-Phenyloxamide derivatives | SERPINE1, SERPINH1, F12 | LMNA 488/4885TRPA1 1091/4885CHRM1 877/4885 |
| US-20230159526-A1 | COMPOUNDS FOR INHIBITING NLRP3 AND USES THEREOF | NLRP3, NLRP1, PYCARD | LMNA 945/4885TRPA1 2453/4885CHRM1 4854/4885 |
| US-20230159445-A1 | STAT INHIBITORY COMPOUNDS AND COMPOSITIONS | STAT5A, STAT5B, STAT3 | LMNA 4768/4885TRPA1 4562/4885CHRM1 4829/4885 |
| US-20120129846-A1 | GAMMA SECRETASE MODULATORS | BACE1, BACE2, PSEN1 | LMNA 652/4885TRPA1 4391/4885CHRM1 1759/4885 |
| US-20090215899-A9 | N-Phenyloxamide derivatives | SERPINE1, SERPINH1, F12 | LMNA 488/4885TRPA1 1091/4885CHRM1 877/4885 |
| US-20230137956-A1 | ALPHA SUBSTITUTED STAT INHIBITORS AND COMPOSITIONS THEREOF | STAT5A, STAT5B, STAT3 | LMNA 4588/4885TRPA1 4745/4885CHRM1 4826/4885 |
| US-20200270230-A1 | µ-OPIOID RECEPTOR AGONIST AND PREPARATION METHOD THEREFOR AND USE THEREOF IN FIELD OF MEDICINE | OPRM1, OPRD1, OPRK1 | LMNA 3988/4885TRPA1 430/4885CHRM1 392/4885 |
| US-20110015190-A1 | GAMMA SECRETASE MODULATORS | BACE1, BACE2, PSEN1 | LMNA 2080/4885TRPA1 4712/4885CHRM1 2481/4885 |
| US-20230265055-A1 | STAT INIHIBITORY COMPOUNDS AND COMPOSITIONS | STAT5B, STAT5A, STAT3 | LMNA 3703/4885TRPA1 4527/4885CHRM1 4829/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.